Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376159 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL3179881 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708629 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL7287734 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL1448119 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL949983 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708628 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL26604823 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL13164545 | 0.95 | ABCB1 (0.47) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL29548192 | 0.93 | MCL1 (0.50) | ABCB1AGTR2KLK7MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1660447-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-5340801-A | Compounds having cholecystokinin and gastrin antagonistic properties | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | BACE1, BACE2, PSEN1 | ABCB1 301/4885AGTR2 71/4885KLK7 4546/4885 |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | ABCB1 285/4885AGTR2 959/4885KLK7 453/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | ABCB1 301/4885AGTR2 71/4885KLK7 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.